Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
**Background:** Pulmonary arterial hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain and syncope. As there is no known cure for PAH, the goal of treatment is to control symptoms and slow disease progression. Sildenafil, a phosphodiesterase-5 inhibitor, has been indicated...
Main Authors: | Ariel Berger, John Edelsberg, Simon Teal, Marko A. Mychaskiw, Gerry Oster |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | http://jheor.scholasticahq.com/article/9871-use-of-sildenafil-in-pulmonary-arterial-hypertension-findings-from-a-u-s-healthcare-claims-database.pdf |
Similar Items
-
Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study
by: Berger Ariel, et al.
Published: (2012-12-01) -
Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder
by: Dukes Ellen, et al.
Published: (2009-07-01) -
Sildenafil in the treatment of pulmonary hypertension
by: O. S. Groznova, et al.
Published: (2016-03-01) -
Sildenafil in the treatment of pulmonary hypertension
by: Christopher F Barnett, et al.
Published: (2006-12-01) -
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study
by: Berger Ariel, et al.
Published: (2012-08-01)